BACKGROUND: Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. OBJECTIVES: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. METHODS: A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. RESULTS: We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 % CI -1.46 to -0.37; I(2) = 21 %) and severity assessed by various scales (standardized difference in means -0.34; 95 % CI -0.59 to -0.10; I(2) = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. CONCLUSION: SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.
BACKGROUND: Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. OBJECTIVES: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. METHODS: A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. RESULTS: We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 % CI -1.46 to -0.37; I(2) = 21 %) and severity assessed by various scales (standardized difference in means -0.34; 95 % CI -0.59 to -0.10; I(2) = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. CONCLUSION: SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.
Authors: Eila Suvanto-Luukkonen; Riitta Koivunen; Helena Sundström; Risto Bloigu; Eija Karjalainen; Leena Häivä-Mällinen; Juha S Tapanainen Journal: Menopause Date: 2005 Jan-Feb Impact factor: 2.953
Authors: J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: Charles L Loprinzi; Jeff A Sloan; Edith A Perez; Susan K Quella; Phillip J Stella; James A Mailliard; Michele Y Halyard; Sandhya Pruthi; Paul J Novotny; Teresa A Rummans Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Katherine M Newton; Diana S M Buist; Nora L Keenan; Lynda A Anderson; Andrea Z LaCroix Journal: Obstet Gynecol Date: 2002-07 Impact factor: 7.661
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Jamie N Justice; Marnie G Silverstein-Metzler; Beth Uberseder; Susan E Appt; Thomas B Clarkson; Thomas C Register; Stephen B Kritchevsky; Carol A Shively Journal: Geroscience Date: 2017-10-28 Impact factor: 7.713
Authors: Kim Pauwaert; An-Sofie Goessaert; Lynn Ghijselings; Thomas F Monaghan; Herman Depypere; Karel Everaert Journal: Int Urogynecol J Date: 2021-01-13 Impact factor: 2.894
Authors: Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian Journal: J Natl Compr Canc Netw Date: 2017-09 Impact factor: 11.908
Authors: Stephanie L Willard; Beth Uberseder; Ashlee Clark; James B Daunais; Warwick D Johnston; David Neely; Adreanna Massey; Jeff D Williamson; Robert A Kraft; J Daniel Bourland; Sara R Jones; Carol A Shively Journal: Neuropharmacology Date: 2015-06-24 Impact factor: 5.250
Authors: Chris Stubbs; Lisa Mattingly; Steven A Crawford; Elizabeth A Wickersham; Jessica L Brockhaus; Laine H McCarthy Journal: J Okla State Med Assoc Date: 2017-05
Authors: Alison J Huang; Steven R Cummings; Michael Schembri; Eric Vittinghoff; Peter Ganz; Deborah Grady Journal: Menopause Date: 2016-03 Impact factor: 2.953
Authors: Kunal C Kadakia; Charles L Loprinzi; Pamela J Atherton; Kelliann C Fee-Schroeder; Amit Sood; Debra L Barton Journal: Support Care Cancer Date: 2015-08-08 Impact factor: 3.603